argenx SEEURONEXT: ARGX

Argenx argenx to Present at Upcoming Investor Conferences

· Issued by argenx SE

Summary by 6ix AI

argenx, a global immunology company, said members of its management team will take part in fireside chats at the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference in September 2026.

Key details

  • Wells Fargo 21st Annual Healthcare Conference: fireside chat on Tuesday, September 8, 2026 at 9:30 a.m. ET in Boston, MA.
  • Morgan Stanley 24th Annual Global Healthcare Conference: fireside chat on Monday, September 14, 2026 at 9:15 a.m. ET in New York, NY.
  • A live webcast will be available in the Investors section of the argenx website, with a replay available for approximately 30 days after each presentation.

6ix AI wrote this summary from the release below and checked it against the release.

argenx to Present at Upcoming Investor Conferences

Your publication date and time will appear here. | Source: argenx SE

Share

September 1, 2026 Amsterdam, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences in September:
Wells Fargo 21st Annual Healthcare Conference. Fireside chat on Tuesday, September 8, 2026 at 9:30 a.m. ET in Boston, MA.
Morgan Stanley 24th Annual Global Healthcare Conference. Fireside chat on Monday, September 14, 2026 at 9:15 a.m. ET in New York, NY.
A live webcast of the presentations may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcasts will be available on the argenx website for approximately 30 days following the presentation.
About argenx

argenx is a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit

www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

Contacts Media:

Ben Petok

bpetok@argenx.com

Investors:

Alexandra Roy

aroy@argenx.com

argenx SE on 6ix

Story so far

Earlier from argenx

Later from argenx

All argenx news releases